Unió Europea -
noruec -
EMA (European Medicines Agency)
gavreto
roche registration gmbh - pralsetinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
Noruega -
noruec -
Statens legemiddelverk
diacomit 250 mg
abacus medicine a/s - stiripentol - kapsel, hard - 250 mg
Noruega -
noruec -
Statens legemiddelverk
diacomit 500 mg
abacus medicine a/s - stiripentol - kapsel, hard - 500 mg